CHMP Give Positive Opinion for New Tecentriq-Based Combination Therapy as an Initial Treatment for Advanced Lung Cancer
Combination of Tecentriq and chemotherapy has demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit
30 Jul 2019Roche has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
This decision is based on results from the Phase III IMpower130 study, which demonstrated that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone (median overall survival [OS]=18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat (ITT) population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with chemotherapy alone (median PFS=7.0 versus 5.5 months; HR=0.64; 95% CI: 0.54–0.77; p<0.0001) in the ITT-WT population. The safety profile of the Tecentriq combination therapy was consistent with that observed in previous studies.
“We are pleased to receive a positive opinion from the CHMP for this Tecentriq-based lung cancer combination for people living with non-squamous non-small cell lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “Lung cancer is a complex disease that requires a range of treatment options. We are now one step closer to providing another important alternative for this difficult-to-treat form of cancer”.
Despite recent advances in the treatment of NSCLC, there is still a need for new options to support a tailored approach to treatment of this complex disease. Lung cancer is the leading cause of cancer death globally. Each year 1.76 million people die as a result of the disease; this translates into more than 4,800 deaths worldwide every day.
Based on the CHMP positive opinion, a final decision regarding the approval of this Tecentriq-based combination is expected from the European Commission in the near future.
For more science news, straight to your inbox, join SelectScience today>>
Related Products
Request Quote for All Products
cobas® infinity laboratory solution
Roche Diagnostics Schweiz AGTo succeed, you need more than systems that work in harmony. You need integration that unlocks exponentially greater performance. Take integration to the next power with cobas® infinity laboratory solution. It was designed from the drawing board for people to work to their full potential. With cobas® infinity laboratory solution powering your lab, performance that was once not possible, is now reality. Sample workflow engine - your engine for change A uniquely simple, yet powerful tool: Visualize your workflow Dynamic decision-making Modify workflow on the fly Personalized for any lab The sample workflow engine integrates the entire sample flow – from pre- to post-analytics – on a single IT solution. Browser-based access - compatible with your existing IT infrastructure Simplifying usage and management of your solution Easy access for any user without client installation Relieves the burden of installation and upgrades Roche continuously monitors the health of your IT solution The browser-based access integrates IT into your lab environment to optimize your asset utilization and experience. Work area concept - personalize your work space Visualize what you need to take care of: On-demand customization for any user and any discipline Comprehensive data filters Intuitive, easy-to-use design Streamlines user work flow The work area concept integrates information in real time so you can work to your full potential. Lean validation - everything you need, nothing you don’t Standardizes decision-making for full compliance Consolidates information on a single screen Target attention on critical data Never lose the focus on results Automatic validation The lean validation integrates key information to accelerate your delivery of high-quality results. cobas® infinity laboratory solution - integration to the next power cobas® infinity is a highly flexible and scalable series of innovative digital products, designed to help you manage all of your tasks and work processes in all of the different work areas. It is a comprehensive management tool designed to keep you in the driver seat. It collects all the data you need and brings it together on your screen.
cobas 8100 Automated Workflow Series
Roche Diagnostics Schweiz AGUsing intelligent robotics, the cobas 8100 series automatically prepares blood samples for immediate testing and post-analytical processing, providing high-speed processing of up to 1,100 samples per hour.